Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers
Authors:
- 14 May 2019
- journal article
- research article
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 44 (6) , 777-785
Abstract
Sirolimus (Rapamune®) exhibits low bioavailability, high variability and moderate food effect following oral administration. This makes therapeutic blood monitoring of sirolimus concentrations necessary for kidney transplant patients. Furthermore, reaching therapeutic blood sirolimus concentrations in renal cancer patients was found to be challenging when the marketed drug was administered alone. A novel, nano-amorphous formulation of the compound was developed and its pharmacokinetic properties were investigated in a dose escalation study in a first-in-human clinical trial. The effect of food at the highest dose on the pharmacokinetic parameters was also assessed.Keywords
This publication has 19 references indexed in Scilit:
- Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow methodEuropean Journal of Pharmaceutics and Biopharmaceutics, 2015
- Rapamycin passes the torch: a new generation of mTOR inhibitorsNature Reviews Drug Discovery, 2011
- mTOR signaling and drug development in cancerNature Reviews Clinical Oncology, 2010
- Rapamycin: An anti-cancer immunosuppressant?Critical Reviews in Oncology/Hematology, 2005
- mTOR-targeted therapy of cancer with rapamycin derivativesAnnals of Oncology, 2005
- Sirolimus: its discovery, biological properties, and mechanism of actionTransplantation Proceedings, 2003
- From Beach to Bedside: History of the Development of SirolimusTherapeutic Drug Monitoring, 2001
- Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipientsBiopharmaceutics & Drug Disposition, 1999
- Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose AdministrationThe Journal of Clinical Pharmacology, 1997
- Measurement of Rapamycin in Whole Blood Using Reverse-Phase High-Performance Liquid ChromatographyTherapeutic Drug Monitoring, 1992